RFK Jr. Wants to Fast-Track Psychedelic Therapy. That's a Disaster in the Making.The New York Times article inaccurately blames Psymposia for the failure of MDMA therapy approval, overshadowing the true complexities of the situation.
The drugmaker that hopes to legalize MDMA is cutting 75% of its staff after the FDA rejected the drugLykos Therapeutics is reducing its staff by 75% after the FDA rejected its MDMA drug for mental health treatment.
RFK Jr. Wants to Fast-Track Psychedelic Therapy. That's a Disaster in the Making.The New York Times article inaccurately blames Psymposia for the failure of MDMA therapy approval, overshadowing the true complexities of the situation.
The drugmaker that hopes to legalize MDMA is cutting 75% of its staff after the FDA rejected the drugLykos Therapeutics is reducing its staff by 75% after the FDA rejected its MDMA drug for mental health treatment.
FDA gives thumbs down to MDMA for now, demanding further researchThe FDA has requested further study on MDMA-assisted therapy for PTSD, dealing a blow to Lykos Therapeutics and the broader psychedelics movement.
Three Studies of MDMA Treatment Retracted by Scientific JournalPsychopharmacology retracted papers on MDMA-assisted therapy due to unethical conduct at a study site.
Opinion | How Psychedelic Research Got High on Its Own SupplyLykos Therapeutics faced a significant setback with the F.D.A.'s rejection of their MDMA PTSD treatment application, raising concerns about trial integrity.
FDA gives thumbs down to MDMA for now, demanding further researchThe FDA has requested further study on MDMA-assisted therapy for PTSD, dealing a blow to Lykos Therapeutics and the broader psychedelics movement.
Three Studies of MDMA Treatment Retracted by Scientific JournalPsychopharmacology retracted papers on MDMA-assisted therapy due to unethical conduct at a study site.
Opinion | How Psychedelic Research Got High on Its Own SupplyLykos Therapeutics faced a significant setback with the F.D.A.'s rejection of their MDMA PTSD treatment application, raising concerns about trial integrity.
FDA panel votes against ecstasy for PTSDThe FDA usually follows advisory committees' advice, with a decision expected on Lykos Therapeutics' drug application by Aug. 11.